Anika Therapeutics (ANIK) Revenue & Revenue Breakdown
Anika Therapeutics Revenue Highlights
Latest Revenue (Y)
$166.66M
Latest Revenue (Q)
$41.92M
Main Segment (Y)
Joint Preservation and Restoration
Main Geography (Y)
UNITED STATES
Anika Therapeutics Revenue by Period
Anika Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $166.66M | 6.67% |
| 2022-12-31 | $156.24M | 5.71% |
| 2021-12-31 | $147.79M | 13.29% |
| 2020-12-31 | $130.46M | 13.83% |
| 2019-12-31 | $114.61M | 8.58% |
| 2018-12-31 | $105.56M | -6.93% |
| 2017-12-31 | $113.42M | 9.71% |
| 2016-12-31 | $103.38M | 11.16% |
| 2015-12-31 | $93.00M | -11.93% |
| 2014-12-31 | $105.59M | 40.64% |
| 2013-12-31 | $75.08M | 5.22% |
| 2012-12-31 | $71.36M | 10.16% |
| 2011-12-31 | $64.78M | 16.60% |
| 2010-12-31 | $55.56M | 38.42% |
| 2009-12-31 | $40.14M | 12.17% |
| 2008-12-31 | $35.78M | 16.06% |
| 2007-12-31 | $30.83M | 14.86% |
| 2006-12-31 | $26.84M | -10.04% |
| 2005-12-31 | $29.84M | 12.73% |
| 2004-12-31 | $26.47M | 71.81% |
| 2003-12-31 | $15.40M | 16.81% |
| 2002-12-31 | $13.19M | 16.57% |
| 2001-12-31 | $11.31M | -30.75% |
| 2000-12-31 | $16.34M | 21.00% |
| 1999-12-31 | $13.50M | -2.88% |
| 1998-12-31 | $13.90M | 15.83% |
| 1997-12-31 | $12.00M | 900.00% |
| 1996-12-31 | $1.20M | -64.71% |
| 1995-08-31 | $3.40M | -27.66% |
| 1994-08-31 | $4.70M | 113.64% |
| 1993-08-31 | $2.20M | - |
Anika Therapeutics generated $166.66M in revenue during NA 2023, up 6.67% compared to the previous quarter, and up 157.89% compared to the same period a year ago.
Anika Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $41.92M | 3.45% |
| 2024-03-31 | $40.52M | -5.70% |
| 2023-12-31 | $42.97M | 3.63% |
| 2023-09-30 | $41.47M | -6.40% |
| 2023-06-30 | $44.30M | 16.82% |
| 2023-03-31 | $37.92M | -4.29% |
| 2022-12-31 | $39.62M | -1.59% |
| 2022-09-30 | $40.26M | 1.53% |
| 2022-06-30 | $39.66M | 8.08% |
| 2022-03-31 | $36.69M | 2.43% |
| 2021-12-31 | $35.82M | -9.40% |
| 2021-09-30 | $39.54M | 3.65% |
| 2021-06-30 | $38.15M | 11.24% |
| 2021-03-31 | $34.29M | 4.91% |
| 2020-12-31 | $32.69M | 3.14% |
| 2020-09-30 | $31.69M | 3.31% |
| 2020-06-30 | $30.68M | -13.33% |
| 2020-03-31 | $35.40M | 18.89% |
| 2019-12-31 | $29.77M | 0.25% |
| 2019-09-30 | $29.70M | -2.37% |
| 2019-06-30 | $30.42M | 23.04% |
| 2019-03-31 | $24.72M | -8.28% |
| 2018-12-31 | $26.96M | 0.63% |
| 2018-09-30 | $26.79M | -12.31% |
| 2018-06-30 | $30.55M | 43.66% |
| 2018-03-31 | $21.26M | -27.64% |
| 2017-12-31 | $29.39M | 8.11% |
| 2017-09-30 | $27.18M | -18.76% |
| 2017-06-30 | $33.46M | 43.09% |
| 2017-03-31 | $23.39M | -18.59% |
| 2016-12-31 | $28.73M | 11.39% |
| 2016-09-30 | $25.79M | -2.98% |
| 2016-06-30 | $26.58M | 19.29% |
| 2016-03-31 | $22.28M | -27.87% |
| 2015-12-31 | $30.89M | 30.46% |
| 2015-09-30 | $23.68M | 3.40% |
| 2015-06-30 | $22.90M | 47.57% |
| 2015-03-31 | $15.52M | -33.26% |
| 2014-12-31 | $23.25M | 5.44% |
| 2014-09-30 | $22.06M | -16.06% |
| 2014-06-30 | $26.27M | -22.74% |
| 2014-03-31 | $34.01M | 60.04% |
| 2013-12-31 | $21.25M | 19.70% |
| 2013-09-30 | $17.75M | -14.76% |
| 2013-06-30 | $20.83M | 36.61% |
| 2013-03-31 | $15.25M | -32.55% |
| 2012-12-31 | $22.61M | 53.09% |
| 2012-09-30 | $14.77M | -24.76% |
| 2012-06-30 | $19.62M | 36.66% |
| 2012-03-31 | $14.36M | -22.14% |
| 2011-12-31 | $18.44M | -0.06% |
| 2011-09-30 | $18.46M | 14.34% |
| 2011-06-30 | $16.14M | 37.51% |
| 2011-03-31 | $11.74M | -20.27% |
| 2010-12-31 | $14.72M | 6.15% |
| 2010-09-30 | $13.87M | -4.35% |
| 2010-06-30 | $14.50M | 16.31% |
| 2010-03-31 | $12.47M | 17.39% |
| 2009-12-31 | $10.62M | -1.61% |
| 2009-09-30 | $10.79M | 13.33% |
| 2009-06-30 | $9.52M | 3.51% |
| 2009-03-31 | $9.20M | 2.62% |
| 2008-12-31 | $8.97M | -2.60% |
| 2008-09-30 | $9.21M | 1.60% |
| 2008-06-30 | $9.06M | 5.98% |
| 2008-03-31 | $8.55M | -11.20% |
| 2007-12-31 | $9.63M | - |
Anika Therapeutics generated $41.92M in revenue during Q2 2024, up 3.45% compared to the previous quarter, and up 110.54% compared to the same period a year ago.
Anika Therapeutics Revenue Breakdown
Anika Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-Orthopedic | $9.86M | $7.95M | $9.70M | - | - |
| Joint Preservation and Restoration | $54.88M | $50.40M | $48.59M | $39.37M | - |
| OA Pain Management | - | $97.89M | $89.50M | - | - |
| Licensing, Milestone and Contract Revenue | - | - | - | - | - |
| Product | - | - | $147.79M | $130.46M | $114.51M |
| Joint Pain Management Therapies | - | - | - | $83.03M | - |
| Manufactured Product, Other | - | - | - | $8.06M | $6.08M |
| Orthobiologics | - | - | - | - | $101.00M |
| Surgical | - | - | - | - | $5.18M |
| Dermal | - | - | - | - | $2.24M |
Anika Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Joint Preservation and Restoration (84.77%), and Non-Orthopedic (15.23%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Orthopedic | $2.36M | $2.60M | $3.11M | $2.31M | $1.84M | $1.53M | $2.78M | $1.82M | $1.82M | - | - | - | - | - | - | - | - | - | - | - |
| Joint Preservation and Restoration | $13.84M | $15.30M | $13.47M | $12.66M | $13.45M | $14.35M | $11.82M | $12.10M | $12.14M | $13.29M | $11.19M | $11.88M | $12.22M | - | - | - | - | - | - | - |
| OA Pain Management | - | - | - | $29.33M | $22.63M | $23.75M | $25.66M | $25.74M | $22.73M | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | - | - | - | - | $36.69M | $35.82M | $39.54M | $38.15M | $34.29M | $32.69M | $31.69M | $30.68M | $35.40M | $29.77M | $29.61M | $30.41M |
| Joint Pain Management Therapies | - | - | - | - | - | - | - | - | - | - | $26.15M | $24.32M | $19.32M | $16.86M | $18.44M | $22.25M | $25.48M | - | - | - |
| Manufactured Product, Other | - | - | - | - | - | - | - | - | - | - | $2.19M | $1.94M | $2.76M | $2.69M | $1.54M | $1.81M | $2.02M | $1.37M | $1.85M | $1.41M |
| Orthopedic Joint Preservation and Restoration Care | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.71M | $6.62M | $7.90M | - | - | - |
| Orthobiologics | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $26.03M | $26.77M | $26.46M |
| Dermal | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.25M | $417.00K | $444.00K |
| Surgical | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.11M | $578.00K | $2.10M |
Anika Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Joint Preservation and Restoration (85.41%), and Non-Orthopedic (14.59%).
Anika Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Europe | $21.72M | $20.64M | $19.58M | $14.18M | $14.74M |
| UNITED STATES | $123.13M | $119.15M | $113.83M | $103.18M | $90.30M |
Anika Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (85.00%), and Europe (15.00%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | $5.97M | $4.97M | $5.42M | $5.67M | $5.66M | $4.67M | $4.88M | $5.29M | $5.80M | $4.77M | $4.24M | $5.09M | $5.48M | $3.04M | $2.95M | $2.91M | $5.28M | $3.35M | $3.94M | $4.93M |
| UNITED STATES | $29.24M | $32.14M | $30.83M | $32.87M | $27.29M | $31.60M | $31.09M | $29.69M | $26.77M | $27.85M | $30.91M | $30.07M | $25.00M | $25.33M | $26.41M | $25.13M | $26.31M | $23.76M | $23.51M | $22.94M |
Anika Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (83.05%), and Europe (16.95%).
Anika Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AVNS | Avanos Medical | $673.30M | $170.40M |
| AORT | Artivion | $354.00M | $98.02M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| AXGN | AxoGen | $159.01M | $47.91M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SRDX | Surmodics | $132.58M | $30.34M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| CVRX | CVRx | $39.30M | $13.37M |
| OSA | ProSomnus | $27.65M | $7.46M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
ANIK Revenue FAQ
What is Anika Therapeutics’s yearly revenue?
Anika Therapeutics's yearly revenue for 2023 was $166.66M, representing an increase of 6.67% compared to 2022. The company's yearly revenue for 2022 was $156.24M, representing an increase of 5.71% compared to 2021. ANIK's yearly revenue for 2021 was $147.79M, representing an increase of 13.29% compared to 2020.
What is Anika Therapeutics’s quarterly revenue?
Anika Therapeutics's quarterly revenue for Q2 2024 was $41.92M, a 3.45% increase from the previous quarter (Q1 2024), and a -5.37% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $40.52M, a -5.70% decrease from the previous quarter (Q4 2023), and a 6.85% increase year-over-year (Q1 2023). ANIK's quarterly revenue for Q4 2023 was $42.97M, a 3.63% increase from the previous quarter (Q3 2023), and a 8.45% increase year-over-year (Q4 2022).
What is Anika Therapeutics’s revenue growth rate?
Anika Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 12.77%, and for the last 5 years (2019-2023) was 45.42%.
What are Anika Therapeutics’s revenue streams?
Anika Therapeutics's revenue streams in c 23 are Non-Orthopedic, and Joint Preservation and Restoration. Non-Orthopedic generated $9.86M in revenue, accounting 15.23% of the company's total revenue, up 24.02% year-over-year. Joint Preservation and Restoration generated $54.88M in revenue, accounting 84.77% of the company's total revenue, up 8.88% year-over-year.
What is Anika Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Anika Therapeutics was Joint Preservation and Restoration. This segment made a revenue of $54.88M, representing 84.77% of the company's total revenue.